Prolonged delivery of peptides by microcapsules

Maulding, H.V.

doi:10.1016/0168-3659(87)90074-5

Cited by 80 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLGA degradation can range from days to months depending on the molecular weight of the polymer, lactide:glycolide ratio, and the size and shape of the delivery system. In 1987, HV Maulding characterized the release profiles of PLGA microparticles (~45 kDa) ranging from 45 to 177 mm and determined that it takes 70 days for 100% loss of the molecular weight of PLGA (Maulding 1987).…”

Section: Polymer Nanoparticlesmentioning

confidence: 99%

Nanotechnology and Nanoparticles

Durazo

Kompella

2011

AAPS Advances in the Pharmaceutical Sciences Series

View full text Add to dashboard Cite

Developing effective therapeutics to treat disorders of the back of the eye is an extremely difficult task due to the inability to deliver therapeutically relevant drug levels to the back of the eye using traditional methods (topical and systemic modes of administration). Innovative techniques and approaches are required to overcome the limitations associated with developing effective therapeutics to treat disorders of the back of the eye. Nanotechnology is a field that advances materials with a nano-dimension and provides several means for innovative design of nanosize drug delivery systems (nanosystems) to overcome biological barriers. Nanosystems based on polymers, lipids, proteins, and carbohydrates hold significant promise in enhancing drug delivery and hence, efficacy of small as well as large molecules intended for treating disorders of the back of the eye.

show abstract

Section: Polymer Nanoparticlesmentioning

confidence: 99%

Nanotechnology and Nanoparticles

Durazo

Kompella

2011

AAPS Advances in the Pharmaceutical Sciences Series

View full text Add to dashboard Cite

show abstract

“…Macromolecules and peptides including bovine serum albumin (BSA; Cohen et al, 1991;Wang et al, 1991;Sah and Chien, 1993), human serum albumin (Hora et al, 1990), calcitonin , bovine growth hormone (Lewis, 1990), horseradish peroxidase (Cohen et al, 1991), interleukin-2 (Hora et al, 1989), interferon-β (Eppstein, 1986), insulin , lypressin (Maulding, 1987), lysozyme (Tabata et al, 1993a), luteinizing hormone-releasing hormone (LHRH) analogs (Anik et al, 1984;Sanders et al, 1984Sanders et al, , 1985Sanders et al, , 1986Hutchinson and Furr, 1985Furr and Hutchinson, 1992;Okada, 1989;Okada et al, 1988Okada et al, , 1991Ogawa et al, 1988;Asano et al, 1989aAsano et al, , b, 1991, and nerve growth factor (Camarata et al, 1992) have been formulated in PLA or PGA homopolymers or PLGA copolymers as controlled release formulations.…”

Section: Poly(lactic Acid) Poly(glycolic Acid) and Their Copolymersmentioning

confidence: 99%

Protein Delivery

2002

Pharmaceutical Biotechnology

View full text Add to dashboard Cite

A major challenge confronting pharmaceutical scientists in the future will be to design successful dosage forms for the next generation of drugs. Many of these drugs will be complex polymers of amino acids (e.g., peptides, proteins), nucleosides (e.g., antisense molecules), carbohydrates (e.g., polysaccharides), or complex lipids.Through rational drug design, synthetic medicinal chemists are preparing very potent and very specific peptides and antisense drug candidates. These molecules are being developed with molecular characteristics that permit optimal interaction with the specific macromolecules (e.g., receptors, enzymes, RNA, DNA) that mediate their therapeutic effects. Rational drug design does not necessarily mean rational drug delivery, however, which strives to incorporate into a molecule the molecular properties necessary for optimal transfer between the point of administration and the pharmacological target site in the body.Like rational drug design, molecular biology is having a significant impact on the pharmaceutical industry. For the first time, it is possible to produce large quantities of highly pure proteins, polysaccharides, and lipids for possible pharmaceutical applications. Like peptides and antisense molecules, the design of successful dosage forms for these complex biotechnology products represents a major challenge to pharmaceutical scientists.Development of an acceptable drug dosage form is a complex process requiring strong interactions between scientists from many different divisions in a pharmaceutical company, including discovery, development, and manufacturing. The series editor, the editors of the individual volumes, and the publisher hope that this new series will be particularly helpful to scientists in the development areas of a pharmaceutical company (e.g., drug metabolism, toxicology, pharmacokinetics and pharmacodynamics, drug ix x Preface to the Series delivery, preformulation, formulation, and physical and analytical chemistry). In addition, we hope this series will help to build bridges between the development scientists and scientists in discovery (e.g., medicinal chemistry, pharmacology, immunology, cell biology, molecular biology) and in manufacturing (e.g., process chemistry, engineering). The design of successful dosage forms for the next generation of drugs will require not only a high level of expertise by individual scientists, but also a high degree of interaction between scientists in these different divisions of a pharmaceutical company.Finally, everyone involved with this series hopes that these volumes will also be useful to the educators who are training the next generation of pharmaceutical scientists. In addition to having a high level of expertise in their respective disciplines, these young scientists will need to have the scientific skills necessary to communicate with their peers in other scientific disciplines. RONALD T. BORCHARLDT Series Editorxi xii Preface sometimes unanticipated formulation challenges. Such problems have plagued efforts to develop ...

show abstract

“…So, in cancer chemotherapy, the delivery of anticancer agent to the target tumor cells in a sufficient amount for a desired period of time is one of the most promising approaches to achieve an excellent clinical therapeutic effect and to overcome the problem of severe side-effects. In order to provide a drug delivery system which displays the slow and continuous release of anticancer agent, polymer microsphere or microcapsule systems using some kinds of biodegradable polymer such as polylactide [ 11, polyoactide-co-glycolide) [2], albumin [3, 41, and fibrinogen [5] have been investigated. Moreover, some approaches to enable the site specific delivery of drugs in vivo using polymer microspheres containing magnetite were reported [6].…”

Section: Introductionmentioning

confidence: 99%